AVXL
Anavex Life Sciences Corp is a clinical stage bio-pharmaceutical company. The Company is engaged in the developments drug candidates to treat Alzheimer\'s disease, other central nervous system (CNS) diseases, and various types of cancer.
Anavex Life Sciences Corp. (AVXL) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (F). The rating has held at C- for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | C+ (2.5) | C+ (2.5) | C- (2.1) | F (0.6) | C+ (2.6) | C- (2.1) |
| 2026-11-10 | C+ (2.5) | C+ (2.5) | C- (2.1) | D- (0.7) | C+ (2.6) | C- (2.1) |
| 2026-11-03 | C+ (2.5) | C+ (2.5) | C- (2.1) | D- (0.8) | C+ (2.7) | C- (2.1) |
| 2026-10-27 | C+ (2.5) | C+ (2.5) | C (2.2) | D (1.2) | C+ (2.6) | C (2.2) |
| 2026-10-20 | C+ (2.5) | C+ (2.5) | C (2.2) | D- (1.1) | C+ (2.6) | C (2.2) |